– AllStripes, a San Francisco-based healthcare technology company dedicated to unlocking treatments for people affected by rare diseases, today announced it has raised $50 million in Series B funding led by Lux Capital, a current investor, joined by JAZZ Venture Partners, Spark Capital, Medidata Solutions, McKesson Ventures, and Maveron. The round also included participation from angel investors including Arif Nathoo, CEO of Komodo Health, and Leila Zegna, Director of the Kabuki Syndrome Foundation.
– Allstripes was founded in 2017, by CEO Nancy Yu and technology developer Onno Faber, following his diagnosis and journey with the rare disease neurofibromatosis type 2. AllStripes has developed a technology platform that generates regulatory-ready evidence to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to securely participate in treatment research online and benefit from their own medical data.
– The funding will support launching 100 new rare disease research programs while expanding global operational footprint, technology and data automation enhancements.
Recent Traction/Milestones
AllStripes is currently partnering with more than 30 patient advocacy organizations across its 40 conditions, supporting more than 3,000 users to date. As a public benefit corporation (PBC), AllStripes is advocating for the importance of real-world evidence in development of treatments and is continuing to build tools that make research more inclusive for the global rare disease community. The Company is committed to transparent data collection and sharing data across the life sciences continuum to advance clinical research.
AllStripes collaborates with various biopharmaceutical companies and other entities on real-world evidence studies, including: HemoShear Therapeutics, Inc., Orphan Disease Center at the University of Pennsylvania, Taysha Gene Therapies, Inc., UCB Biopharma SRL, and Novartis Pharma AG. These joint research programs aim to enhance clinical understanding of rare disease treatment research. AllStripes and the University of Pennsylvania’s Orphan Disease Center are focused on clinical understanding of Lesch-Nyhan disease and Crigler Najjar syndrome type 1, with the goal of facilitating therapeutic discovery for both conditions. One of AllStripes’ most recent partnerships with HemoShear Therapeutics aims to gather real-world evidence on patients’ medical experience with serious metabolic diseases through the Journey to Understand MMA and PA (JUMP) study.
“Beginning research on a rare condition can feel like being dropped into a new world without a map and we are on a mission to change that with data,” said Nancy Yu, CEO and Co-founder, AllStripes. “We’re proud that so many of our current investors have recognized the progress we’ve made and are continuing to support our vision to transform rare disease research. This investment will allow us to better support the rare disease community, where each person’s experience is essential to understanding disease progression – ultimately leading to new treatments for rare disease patients around the globe.”
